John G Ullman & Associates Inc. Has $7.43 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

John G Ullman & Associates Inc. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,005 shares of the medical research company’s stock after selling 623 shares during the period. Thermo Fisher Scientific comprises about 1.2% of John G Ullman & Associates Inc.’s investment portfolio, making the stock its 23rd biggest position. John G Ullman & Associates Inc.’s holdings in Thermo Fisher Scientific were worth $7,434,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. WCM Investment Management LLC lifted its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares during the last quarter. Phoenix Holdings Ltd. raised its stake in shares of Thermo Fisher Scientific by 21.4% in the third quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after acquiring an additional 1,654 shares during the last quarter. DMC Group LLC grew its position in shares of Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after buying an additional 84 shares during the period. S. R. Schill & Associates grew its holdings in Thermo Fisher Scientific by 106.3% during the fourth quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after purchasing an additional 792 shares during the period. Finally, Check Capital Management Inc. CA acquired a new position in Thermo Fisher Scientific during the third quarter valued at approximately $219,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO traded up $3.19 during midday trading on Friday, reaching $544.71. The company had a trading volume of 1,037,033 shares, compared to its average volume of 1,538,783. The company’s 50 day moving average price is $571.39 and its 200 day moving average price is $527.11. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. The stock has a market cap of $207.92 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. During the same period in the previous year, the firm earned $5.40 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.10%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Barclays lowered shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $475.00 to $555.00 in a research note on Wednesday, January 24th. TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Finally, Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $604.69.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.